Circulating Tumor Cells Prognostic Technologies Market

Industry Outlook

The circulating tumor cells prognostic technologies market is expected to reach $12,443.3 million by 2026, up from $2,324.7 million in 2017, with a compounded annual growth rate (CAGR) of 20.8% from 2018 to 2026. As per the latest research findings of the World Health Organization (WHO) for 2018, cancer is the second-largest cause of death globally, with an estimation of 9.6 million deaths in 2018. Worldwide, approximately 1 in 6 deaths occur due to cancer, with 70% of the deaths occurring in low- and middle-income countries.

Cancer is a universal term for a group of diseases that affect different parts of the human body; it is also known as a neoplasm or malignant tumor. Cancer is the rapid creation of abnormal cells that grow from their site of origin and invade other organs through a process known as metastasis, which is usually facilitated by circulating tumor cells. Metastasis is the major cause of death in cancer patients.

Market Synopsis

Technological advancement in the cell enrichment segment will drive the circulating tumor cells market.

Cell enrichment technology currently dominates the circulating tumor cell prognostic technology market. Recent technological advancement in cell enrichment techniques such as filtration, centrifugation, and immunomagnetic methods has resulted in improvised CTC functional characterization, which finds prominence in disease diagnosis and target therapy. Another factor that drives the cell enrichment technology market is its increased adoption in biotechnology industries due to its excellent accuracy and reliable methodology. Cell detection technology will foster impressive growth during the forecast period owing to the introduction of innovative and reproducible molecular biology techniques, such as the isolation of CTC clusters from unprocessed blood. Standardization of optical methods in cell detection has resulted in multicenter clinical trial studies.

The rising incidence of breast cancer in women throughout the globe has resulted in positive traction for CTC’s prognostic technologies market.

Breast cancer is the most common type of cancer in women worldwide, with a variegated prevalence rate ranging from 19.3 cases per 100,000 women in East Africa to 89.7 cases per 100,000 women in the Western European region. In developing nations, breast cancer is diagnosed in late stages, which results in a low survival rate. Researchers throughout the globe are developing biomarkers such as CK3-11D5 and HER2 for the effective diagnosis of non-metastatic breast cancer in women. Prostate cancer will exhibit impressive growth during the forecast period on account of factors such as old age and testosterone imbalance in men. The prevalence rate is high in developed regions such as Europe and North America as people consume diets rich in fat, such as dairy products and red meat, which stimulate the excessive production of testosterone, leading to the onset of prostate cancer. Epic Sciences, Inc., has developed the AR-V7 liquid biopsy test for the accurate prognosis of patients suffering from metastatic prostate cancer.

The Asia Pacific market is driven by the increasing number of patients suffering from cancer and increased funding in R&D to develop CTC’s prognostic technologies.

With 45% of the regional market, North America currently holds the largest share. The key parameters responsible for its dominance are the rising prevalence of cancer and increasing public health awareness, resulting in early diagnosis. A few key players, such as AVIVA Biosciences and Epic Sciences, Inc., have catered to the prognostic needs of prostate and breast cancer in North America. According to World Health Organization (WHO) 2015 statistics, cancer is responsible for 20% of deaths in Europe. The European market for CTC prognostic technologies is being driven by developed healthcare infrastructure and effective cancer treatment guidelines. Asia Pacific serves as a lucrative market on account of factors such as the increasing number of patients suffering from cancer and excellent research activities pertaining to the development of biomarkers and antigens for cancer detection.

Periods of History and Forecast

This research report presents the analysis of each segment from 2016 to 2026, considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

To determine market estimation and compounded annual growth rate (CAGR), qualitative and quantitative market analyses were performed. The market is divided into three parts: technology, application, and geography.

Market estimation and compounded annual growth rate (CAGR) for the report on circulating tumor cells prognostic technologies were determined by applying organic and inorganic market analysis. The technological innovations pertaining to the different types of CTCs being applied for the prognosis of cancer are thoroughly discussed in the scope of the report. The key players spearheading the circulating tumor cells prognostic technologies market are Celula, Inc., Advanced Cell Diagnostics, Inc., Epic Sciences, Inc., AdnaGen GmbH, Fluxion Biosciences, Inc., AVIVA Biosciences Corporation, Rarecells USA, Inc., Vitatex, Inc., Silicon Biosystems S.p.A., and Veridex, LLC.

Key questions are answered in this report.

• What are the market estimation and compound annual growth rate (CAGR) for CTC’s prognostic technologies market?
• Who are the key players actively engaged in developing CTC’s prognostic technologies?
• What are the latest market trends and the level of competition existing among key players in the CTC’s prognostic technologies market?
• Which is the leading and fastest-growing technology segment in the CTC’s prognostic technologies market?
• Which is the leading and fastest-growing application segment in the CTC’s prognostic technologies market?
• Which is the leading and fastest-growing regional segment in the CTC’s prognostic technologies market?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global CTCPT Market Portraiture
2.2. Global CTCPT Market, by Technology, 2017 (US$ Mn)
2.3. Global CTCPT Market, by Application, 2017 (US$ Mn)
2.4. Global CTCPT Market, by Geography, 2017 (US$ Mn)

Chapter 3. Circulating Tumor Cells Prognostic Technologies (CTCPT) Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global CTCPT Market, by Key Players, 2017

Chapter 4. Global Circulating Tumor Cells Prognostic Technologies (CTCPT) Market, by Technology
4.1. Overview
4.2. Tumor Cells Enrichment
4.2.1. Centrifugation
4.2.2. Filtration
4.2.3. Immunological and Immunomagnetic Methods
4.3. Tumor Cells Detection
4.3.1. Molecular Methods
4.3.2. Optical Methods

Chapter 5. Global Circulating Tumor Cells Prognostic Technologies (CTCPT) Market, by Application
5.1. Overview
5.2. Breast Cancer
5.3. Prostate Cancer
5.4. Colorectal Cancer
5.5. Others (Pancreatic, Ovarian Cancer etc.)

Chapter 6. Global Circulating Tumor Cells Prognostic Technologies (CTCPT) Market, by Geography
6.1. Overview
6.2. North America CTCPT Market Analysis, 2016 – 2026
6.2.1. North America CTCPT Market, by Technology, 2016 – 2026 (US$ Mn)
6.2.2. North America CTCPT Market, by Application, 2016 – 2026 (US$ Mn)
6.2.3. North America CTCPT Market, by Country, 2016 – 2026 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe CTCPT Market Analysis, 2016 – 2026
6.3.1. Europe CTCPT Market, by Technology, 2016 – 2026 (US$ Mn)
6.3.2. Europe CTCPT Market, by Application, 2016 – 2026 (US$ Mn)
6.3.3. Europe CTCPT Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific CTCPT Market Analysis, 2016 – 2026
6.4.1. Asia Pacific CTCPT Market, by Technology, 2016 – 2026 (US$ Mn)
6.4.2. Asia Pacific CTCPT Market, by Application, 2016 – 2026 (US$ Mn)
6.4.3. Asia Pacific CTCPT Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.4.3.1. China
6.4.3.2. Japan
6.4.3.3. Rest of Asia Pacific
6.5. Latin America CTCPT Market Analysis, 2016 – 2026
6.5.1. Latin America CTCPT Market, by Technology, 2016 – 2026 (US$ Mn)
6.5.2. Latin America CTCPT Market, by Application, 2016 – 2026 (US$ Mn)
6.5.3. Latin America CTCPT Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East and Africa CTCPT Market Analysis, 2016 – 2026
6.6.1. MEA CTCPT Market, by Technology, 2016 – 2026 (US$ Mn)
6.6.2. MEA CTCPT Market, by Application, 2016 – 2026 (US$ Mn)
6.6.3. MEA CTCPT Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA

Chapter 7. Company Profiles
7.1. AdnaGen GmbH
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Technology Portfolio
7.1.4. News Coverage
7.2. Advanced Cell Diagnostics, Inc.
7.3. AVIVA Biosciences Corporation
7.4. Celula, Inc.
7.5. Epic Sciences, Inc.
7.6. Fluxion Biosciences, Inc.
7.7. Rarecells USA, Inc.
7.8. Vitatex, Inc.
7.9. Veridex, LLC.
7.10. Silicon Biosystems, S.p.A.

List of Figures

FIG. 1 Circulating Tumor Cells Prognostic Technologies (CTCPT) Market: Research Methodology
FIG. 2 CTCPT Market Segmentation
FIG. 3 Global CTCPT Market, by Technology, 2017 (US$ Mn)
FIG. 4 Global CTCPT Market, by Application, 2017 (US$ Mn)
FIG. 5 Global CTCPT Market, by Geography, 2017 (US$ Mn)
FIG. 6 Attractive Investment Proposition: by Geography, 2017
FIG. 7 Competitive Analysis: Global CTCPT Market, by Key Players, 2017
FIG. 8 Global Centrifugation Market for Circulating Tumor Cells Prognostic Technologies, 2016 – 2026 (US$ Mn)
FIG. 9 Global Filtration Market for Circulating Tumor Cells Prognostic Technologies, 2016 – 2026 (US$ Mn)
FIG. 10 Global Immunological and Immunomagnetic Methods Market for Circulating Tumor Cells Prognostic Technologies, 2016 – 2026 (US$ Mn)
FIG. 11 Global Molecular Methods Market for Circulating Tumor Cells Prognostic Technologies, 2016 – 2026 (US$ Mn)
FIG. 12 Global Optical Methods Market for Circulating Tumor Cells Prognostic Technologies, 2016 – 2026 (US$ Mn)
FIG. 13 Global Breast Cancer Market for Circulating Tumor Cells Prognostic Technologies, 2016 – 2026 (US$ Mn)
FIG. 14 Global Prostate Cancer Market for Circulating Tumor Cells Prognostic Technologies, 2016 – 2026 (US$ Mn)
FIG. 15 Global Colorectal Cancer Market for Circulating Tumor Cells Prognostic Technologies, 2016 – 2026 (US$ Mn)
FIG. 16 Global Other Applications Market for Circulating Tumor Cells Prognostic Technologies, 2016 – 2026 (US$ Mn)
FIG. 17 U.S. CTCPT Market, 2016 – 2026 (US$ Mn)
FIG. 18 Canada CTCPT Market, 2016 – 2026 (US$ Mn)
FIG. 19 U.K. CTCPT Market, 2016 – 2026 (US$ Mn)
FIG. 20 Germany CTCPT Market, 2016 – 2026 (US$ Mn)
FIG. 21 Rest of Europe CTCPT Market, 2016 – 2026 (US$ Mn)
FIG. 22 China CTCPT Market, 2016 – 2026 (US$ Mn)
FIG. 23 Japan CTCPT Market, 2016 – 2026 (US$ Mn)
FIG. 24 Rest of Asia Pacific CTCPT Market, 2016 – 2026 (US$ Mn)
FIG. 25 Brazil CTCPT Market, 2016 – 2026 (US$ Mn)
FIG. 26 Mexico CTCPT Market, 2016 – 2026 (US$ Mn)
FIG. 27 Rest of Latin America CTCPT Market, 2016 – 2026 (US$ Mn)
FIG. 28 GCC CTCPT Market, 2016 – 2026 (US$ Mn)
FIG. 29 Rest of MEA CTCPT Market, 2016 – 2026 (US$ Mn)

List of Tables

TABLE 1 Global Circulating Tumor Cells Prognostic Technologies (CTCPT) Market Portraiture
TABLE 2 Global CTCPT Market, by Technology, 2016 – 2026 (US$ Mn)
TABLE 3 Global Tumor Cells Enrichment Market for Circulating Tumor Cells Prognostic Technologies, 2016 – 2026 (US$ Mn)
TABLE 4 Global Tumor Cells Detection Market for Circulating Tumor Cells Prognostic Technologies, 2016 – 2026 (US$ Mn)
TABLE 5 Global CTCPT Market , by Application, 2016 – 2026 (US$ Mn)
TABLE 6 Global CTCPT Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 7 North America CTCPT Market, by Technology, 2016 – 2026 (US$ Mn)
TABLE 8 North America CTCPT Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 9 North America CTCPT Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 10 Europe CTCPT Market, by Technology, 2016 – 2026 (US$ Mn)
TABLE 11 Europe CTCPT Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 12 Europe CTCPT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 13 Asia Pacific CTCPT Market, by Technology, 2016 – 2026 (US$ Mn)
TABLE 14 Asia Pacific CTCPT Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 15 Asia Pacific CTCPT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 16 Latin America CTCPT Market, by Technology, 2016 – 2026 (US$ Mn)
TABLE 17 Latin America CTCPT Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 18 Latin America CTCPT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 19 Middle East and Africa CTCPT Market, by Technology, 2016 – 2026 (US$ Mn)
TABLE 20 Middle East and Africa CTCPT Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 21 Middle East and Africa CTCPT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 22 AdnaGen GmbH: Company Snapshot (Business Description; Financial Information; Technology Portfolio; Key Developments)
TABLE 23 Advanced Cell Diagnostics, Inc.: Company Snapshot (Business Description; Financial Information; Technology Portfolio; Key Developments)
TABLE 24 AVIVA Biosciences Corporation: Company Snapshot (Business Description; Financial Information; Technology Portfolio; Key Developments)
TABLE 25 Celula, Inc.: Company Snapshot (Business Description; Financial Information; Technology Portfolio; Key Developments)
TABLE 26 Epic Sciences, Inc.: Company Snapshot (Business Description; Financial Information; Technology Portfolio; Key Developments)
TABLE 27 Fluxion Biosciences, Inc.: Company Snapshot (Business Description; Financial Information; Technology Portfolio; Key Developments)
TABLE 28 Rarecells USA, Inc.: Company Snapshot (Business Description; Financial Information; Technology Portfolio; Key Developments)
TABLE 29 Vitatex, Inc.: Company Snapshot (Business Description; Financial Information; Technology Portfolio; Key Developments)
TABLE 30 Veridex, LLC: Company Snapshot (Business Description; Financial Information; Technology Portfolio; Key Developments)
TABLE 31 Silicon Biosystems, S.p.A.: Company Snapshot (Business Description; Financial Information; Technology Portfolio; Key Developments)